Medical/Pharmaceuticals

DNV LAUNCHES ACCREDITATION FOR AMBULATORY SURGERY CENTERS

New offering builds on DNV's value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes HOUSTON, Dec. 10, 2025 /PRNewswire/ -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory...

2025-12-10 22:16 2666

Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006

HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals") and Formation Bio today announced Formation Bio's acquisition of worldwide rights, excludingGreater China, to LNK01...

2025-12-10 22:05 3686

Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics

Two leading entities in cancer research pledge scientific collaboration to advance precision oncology. HAMBURG, Germany and ROCHESTER, N.Y., Dec. 10, 2025 /PRNewswire/ -- Indivumed is excited to announce its partnership with the world-renowned Wilmot Cancer Institute at theUniversity of Rocheste...

2025-12-10 21:00 2492

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial. HONG KONG, Dec. 10, 2025 ...

2025-12-10 17:15 2476

Berlin Heals Welcomes Rob ten Hoedt as New Chairman of the Board

ZUG, Switzerland, Dec. 10, 2025 /PRNewswire/ -- Berlin Heals Holding AG (Zug, Switzerland) is pleased to announce the appointment of Rob ten Hoedt as the new Chairman of the Board of Directors. "We are thrilled to welcome someone of Rob ten Hoedt's caliber to the Board," saidMarko Bagaric, Co-fo...

2025-12-10 17:00 1162

Stay True to Our Original Aspiration, Forge Ahead into the Future|Alphamab Oncology 2025 R&D Day Successfully Held

SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its "Stay True to Our Original Aspiration, Forge Ahead into the Future" 2025 R&D Day inShanghai. The event focused on the latest advancements in the field of antibody-drug c...

2025-12-10 14:20 1804

DKSH Healthcare Launches Three-Part Whitepaper Series Showcasing Asia Pacific's Growing Healthcare Outsourcing Opportunity

DKSH Business Unit Healthcare Launches a three-part whitepaper series to help healthcare and life science companies explore industry trends and current market pressures to re-think commercial go-to market approaches in theAsia Pacific region. The whitepaper series demonstrates how strategic Comme...

2025-12-10 14:00 1645

Beijing 101 Launches Tri-Action Scalp Revival Treatment, The Ultimate Multi-Technology Scalp Rejuvenation Solution

SINGAPORE, Dec. 10, 2025 /PRNewswire/ -- Beijing 101 Hair Consultants is thrilled to announce the launch of its latest treatment innovation – the  Tri-Action Scalp Revival Treatment – a systematic, multi-technology hair and scalp treatment that cleanses, nourishes, and rejuvenates the scalp throug...

2025-12-10 10:00 1372

D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs

SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a$108 million Series B financing round. The funding round was backed by a distinguished group ...

2025-12-10 09:30 2373

Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights

* Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential * Synergistic and complementary to Lee's Pharm's existing products pipeline, and * Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global ...

2025-12-10 08:00 2881

AI CAD-OCI Integration Underway: ALL CONEC Begins Validation of Digital Prosthetic Data Workflow

SEOUL, South Korea, Dec. 9, 2025 /PRNewswire/ -- ALL CONEC has been chosen as a participant in the Dream Venture Star 11 Oracle × Uclick Program and will begin validating a unified data workflow for digital prosthetic production. The initiative focuses on integrating design, fabrication, and insp...

2025-12-09 19:55 1160

ISLAND HOSPITAL NAMED MALAYSIA'S FIRST FLAGSHIP MEDICAL TOURISM HOSPITAL

GEORGETOWN, Malaysia, Dec. 9, 2025 /PRNewswire/ -- Island Hospital is the winner ofMalaysia's first Flagship Medical Tourism Hospital (FMTH) programme, a recognition of its consistent standards in care, safety and patient experience for international patients.

2025-12-09 18:18 1712

VSure and HEYDOC Health Introduce CareConnect Suite, Transforming SME Protection and Digital Healthcare in Malaysia

KUALA LUMPUR, Malaysia, Dec. 9, 2025 /PRNewswire/ -- In a move that reflects the shifting expectations ofMalaysia's modern workforce, VSure Group and virtual healthcare provider HEYDOC Health have jointly launchedCareConnect Suite , a new digital ecosystem aimed at closing long-standing gaps in em...

2025-12-09 15:58 1305

Sweden Recommends: A Dose of Northern Lights Therapy

STOCKHOLM, Dec. 9, 2025 /PRNewswire/ -- As the world's first country to be prescribed for its health benefits,Sweden is now shining a light on one of its most awe-inducing wellness experiences. Aurora Borealis – the original arctic light therapy...

2025-12-09 15:53 1030

Greenyn Biotechnology Launches Insumate® mcIRBP-19 Bitter Melon Peptide, Targeting the Billion-Dollar Health Supplement Market

TAICHUNG, Dec. 9, 2025 /PRNewswire/ -- Backed by New Medical Association Certification, Insumate® Becomes the Only Bitter Melon Peptide Globally Recognized by FDA-NDI, SNQ, and the Taiwan Complementary Medicine Society (TCMS). As global demand for scientifically validated metabolic health ingred...

2025-12-09 10:30 1413

Therme Group acquires full Thermengruppe Josef Wund portfolio through Therme Horizon, integrating all four Wund-origin destinations into its global platform

MUNICH, Dec. 9, 2025 /PRNewswire/ -- Therme Group, a leading developer, owner and operator shaping the future of wellbeing infrastructure, today announced the acquisition of three thermal wellbeing destinations — Euskirchen, Sinsheim, and Titisee-Neustadt — from the Josef Wund Foundation. The tra...

2025-12-09 09:00 1732

Inheritance + Innovation + Development: The "Co-development" Path of Hakka Medicine and Traditional Chinese Medicine

HONG KONG, Dec. 9, 2025 /PRNewswire/ -- From November 23 to 25, the Seventh World Hakka Entrepreneurs Convention was held in Meizhou,Guangdong. The conference, with the theme of "Gather Global Hakka Entrepreneurs • Facilitate High-Quality Development," upheld the principles of "openness, innovati...

2025-12-09 08:00 1333

EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide

PROVIDENCE, R.I., Dec. 9, 2025 /PRNewswire/ -- EpiVax, Inc. , with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces the publ...

2025-12-09 03:11 1261

Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

* In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early stage breast cancer. FLORENCE, Italy and NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Menarini Gro...

2025-12-09 03:05 1607

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement – – Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes – – Favorable safety profile with no treatment-related serious adverse e...

2025-12-08 22:22 1217
1 ... 9101112131415 ... 394

Week's Top Stories